Parabilis Medicines (PBLS) Stock Price, News & Analysis

Company Overview

Parabilis Medicines, Inc. is a biopharmaceutical company focused on discovering and developing medicines for patients with serious diseases. The company’s activities include advancing novel therapeutic candidates through preclinical research and clinical development.

Publicly available information about Parabilis Medicines is limited, and specific details regarding its product portfolio, lead development programs, geographic operations and executive leadership are not sufficiently established to describe them accurately.

Key Stats

• Today's Range: $24.80 to $26.44
• 50-Day Range: $25.18 to $41.73
• 52-Week Range: $24.51 to $42.49
• Volume: 954,611 shs
• Average Volume: 1.40 million shs
• Market Capitalization: $3.11 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $41.67
• Consensus Rating: Moderate Buy

Parabilis Medicines Stock Analysis - MarketRank™

Parabilis Medicines scored higher than 42% of companies evaluated by MarketBeat, and ranked 654th out of 870 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Parabilis Medicines has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 1 strong buy rating, 4 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Parabilis Medicines has a consensus price target of $41.67, representing about 65.5% upside from its current price of $25.18.

Amount of Analyst Coverage

Parabilis Medicines has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Parabilis Medicines are expected to grow in the coming year, from ($3.09) to ($2.00) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Parabilis Medicines is -11.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Parabilis Medicines is -11.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.69% of the float of Parabilis Medicines has been sold short.

Short Interest Ratio / Days to Cover

Parabilis Medicines has a short interest ratio ("days to cover") of 4.84.

Change versus previous month

Short interest in Parabilis Medicines has recently increased by 35.61%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Parabilis Medicines does not currently pay a dividend.

Dividend Growth

Parabilis Medicines does not have a long track record of dividend growth.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.40

News Sentiment

Parabilis Medicines has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Parabilis Medicines this week, compared to 3 articles on an average week.

MarketBeat Follows

Only 1 people have added Parabilis Medicines to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Parabilis Medicines insiders have not sold or bought any company stock.

Percentage Held by Institutions

Parabilis Medicines has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 10/15/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:PBLS
• CIK: 1657677
• Web: parabilismed.com
• Phone: 617-945-9510
• Fax: N/A
• Employees: 145
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Parabilis Medicines: $41.67
• High Price Target: $45.00
• Low Price Target: $40.00
• Potential Upside/Downside: +65.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.71
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 17.91
• Quick Ratio: 17.91

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 123,530,000
• Free Float: N/A
• Market Cap: $3.11 billion
• Optionable: N/A
• Beta: N/A